Ibrutinib

1. Ibrutinib is an oral targeted therapy drug mainly used to treat B-cell lymphoma and chronic lymphocytic leukemia.
2. Ibrutinib works by inhibiting Bruton tyrosine kinase (BTK) in the B cell receptor signaling pathway, thereby preventing the growth and spread of cancer cells.
3. Ibrutinib has proven to have significant efficacy in the treatment of refractory or relapsed chronic lymphocytic leukemia, small lymphocytic leukemia, lymphoma, diffuse large B-cell lymphoma and other diseases in clinical trials.
4. Ibrutinib can be used alone or in combination with other drugs, such as rituximab or chemotherapy drugs.

Ibrutinib is widely used in the pharmaceutical field.